The UK: merged RDEC and ERIS
For accounting periods beginning on or after 1 April 2024, the old SME and RDEC schemes are replaced by two reliefs that share the same qualifying-expenditure rules [source]:
- The merged R&D expenditure credit (RDEC). A taxable expenditure credit at 20% of qualifying R&D expenditure (different rates apply to ring-fenced trades). It can be claimed by companies that are trading, chargeable to Corporation Tax, and have a project that meets the definition of R&D. Because the credit is trading income, it is itself liable to Corporation Tax, so the net cash benefit is lower than 20% [source] [source].
- Enhanced R&D intensive support (ERIS). This is only for loss-making, R&D-intensive SMEs. You deduct an extra 86% of qualifying costs (on top of the 100% already deducted), making a 186% deduction in total, and you may claim a payable tax credit of up to 14.5% of the surrenderable loss. That payable credit is not liable to tax. To be R&D-intensive, relevant R&D expenditure must be at least 30% of total expenditure, including connected companies [source] [source].
You cannot claim both schemes for the same expenditure. If you are eligible for ERIS you may instead choose the merged RDEC scheme [source]. Budget 2026 materials confirm that, for financial years 2026 to 2027 and 2027 to 2028, the RDEC rate remains 20%, the ERIS additional deduction 86%, the ERIS payable credit 14.5%, and the intensity threshold 30% [source].
In both schemes the credit you receive in an accounting period cannot exceed a PAYE cap, unless you are exempt. The cap is £20,000 plus 300% of the company's relevant PAYE and National Insurance contributions for the period; under merged RDEC, any excess is carried forward [source]. There are also restrictions on some overseas expenditure.
How a UK claim works
Before you claim, HMRC says you must check the steps required to claim correctly, including whether you need to tell HMRC that you plan to claim, and you must submit the additional information that HMRC requires [source]. SMEs may be able to apply for advance assurance that a claim will be accepted.
Qualifying R&D is a legal test, not a branding exercise. Building or training a model may qualify, or it may not, depending on whether the work meets HMRC's definition of R&D for tax purposes, including the treatment of software. This article does not apply that test to any project. A tax adviser who is familiar with the current guidelines is the right person to do that, and to prepare the claim.
R&D relief sits alongside, and is separate from, UK grant funding. Grants are covered in UK grants for AI: Innovate UK, UKRI and ARIA explained. Receiving a grant can affect what expenditure you may treat as qualifying, so tell your adviser about any award.
The US: the research credit and section 174A
The U.S. credit for increasing research activities sits in Internal Revenue Code section 41 and is claimed on Form 6765. The Internal Revenue Service describes two ways to work it out [source] [irs-6765]:
- The regular credit: generally 20% of the excess of the year's qualified research expenses (QREs) over a base amount.
- The alternative simplified credit, which you may elect: 14% of QREs over 50% of the average QREs for the three preceding tax years.
Startups with little or no income-tax liability may be able to use part of the credit against payroll taxes. A "qualified small business" for this election is a corporation or partnership with gross receipts of less than $5 million for the tax year, and no gross receipts for any tax year before the five-tax-year period ending with that year. A qualified small business may elect to apply up to $500,000 of the research credit against the employer portion of social security tax and then Medicare tax. The election must be made on a timely original income-tax return, including extensions; it cannot be made on an amended return. You then claim it on the employment-tax return for the first quarter that begins after that income-tax return is filed, using Form 8974. You cannot make the election for a tax year if you have already made it for five or more preceding tax years [source] [irs-6765] [source].
Separately, Public Law 119-21 (the Act commonly known as the One Big Beautiful Bill Act) added section 174A. For tax years beginning after 31 December 2024, taxpayers may deduct domestic research and experimental expenditures in the year they are paid or incurred, or may elect to capitalise them and amortise them over at least 60 months. The same law provides transition options for unamortised amounts from tax years beginning after 31 December 2021 and before 1 January 2025; the IRS points to Revenue Procedure 2025-28 for those options [irs-6765].
For tax years beginning after 2025, Section G of Form 6765 (business component information) is required, subject to the form instructions [irs-6765].
How this sits with grants and other funding
Tax relief is not a substitute for a grant, and a grant is not a substitute for tax relief. Many AI companies claim relief on their own R&D while also applying for public grants. The two interact, so keep records that separate qualifying R&D costs from grant-funded costs where the rules require it.
For U.S. federal grants, start with our article on NSF SBIR and STTR for AI startups. For a view of how grants, credits, tax relief and equity fit together, see the AI startup funding stack.
Rates, caps and forms change. Confirm the rules for your own accounting period on the HMRC or IRS pages, or with a qualified adviser, before you file.
